Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.45 |
| ▸ | PDE4A | P27815 | 3/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030804 | 0.85 | ACHE (0.43) | CNR1CNR2KDM4EALDH1A1MAPK1 | |
| SCHEMBL20232746 | 0.83 | PPARG (0.42) | CNR1CNR2PPARGPPARAPDE4B | |
| SCHEMBL9191728 | 0.80 | CNR1 (0.59) | CNR1CNR2PPARGPPARAKDM4E | |
| SCHEMBL14610813 | 0.79 | IKBKB (0.63) | CNR1CNR2PPARGPPARAPDE4B | |
| SCHEMBL8400954 | 0.78 | ALDH1A1 (0.42) | CNR1CNR2ALDH1A1TSHRCYP3A4 | |
| SCHEMBL11560594 | 0.78 | PPARG (0.44) | CNR1CNR2PPARGPPARAKDM4E | |
| SCHEMBL18970435 | 0.78 | PTGER2 (0.49) | GAACTSACYP1A1CYP1A2CYP2E1 | |
| Zinc Ion SCHEMBL9191725 | 0.78 | CNR1 (0.56) | CNR1CNR2PPARGPPARAKDM4E | |
| Methoxy Aucuparin SCHEMBL8420787 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL2096573 | 0.77 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805674-B | Polymeric phosphine ligands, transition metal complexes comprising same, preparation and use thereof | 中国科学院上海有机化学研究所 | 2023-08-11 | — | — | CN | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-114805674-A | Polymeric phosphine ligands, transition metal complexes comprising same, preparation and use thereof | 中国科学院上海有机化学研究所 | 2022-07-29 | — | — | CN | disclosed |
| CN-108017479-B | Method for producing aromatic compound | 东曹株式会社 | 2022-07-29 | — | — | CN | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-13 | — | — | US | disclosed |
| US-7560488-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-14 | — | — | US | disclosed |
| US-7371755-B1 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2008-05-13 | — | — | US | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| EP-1214317-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019822-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | CNR1 4662/4885CNR2 4111/4885PPARG 746/4885 |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | CNR1 4745/4885CNR2 4848/4885PPARG 2893/4885 |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | CNR1 4745/4885CNR2 4848/4885PPARG 2893/4885 |
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | CNR1 4745/4885CNR2 4848/4885PPARG 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.